Peer-reviewed veterinary case report
Dendritic cell therapy helps dogs live longer after spleen cancer
By Spiller, V et al.·Published in Veterinary journal (London, England : 1997)·2024·PetBioCell GmbH, Germany·View original on PubMed →
PetCaseFinder translated the abstract of this peer-reviewed paper into plain English so pet owners can read it. We do not publish original research — every detail traces back to the citation above. How we work →
Original publication title: Prospective study of successful autologous dendritic cell therapy in dogs with splenic stage II hemangiosarcoma.
- Species:
- dog
Plain-English summary
A group of dogs with stage II hemangiosarcoma (a type of aggressive cancer) affecting the spleen were treated with a new therapy using their own immune cells after having their spleens removed. Out of 42 dogs that received this treatment, those who completed the full therapy (at least three vaccine doses) had a median survival time of about 256 days, with some living over a year. This therapy showed promise as a potential alternative to traditional treatments, although more research is needed to confirm its effectiveness.
People also search for: dog hemangiosarcoma treatment · splenic cancer in dogs · dog cancer survival rates · dendritic cell therapy for dogs · dog spleen removal recovery
Abstract
Hemangiosarcoma is an aggressive tumour that most frequently occurs in larger, middle-aged dogs of certain breeds. The spleen is the most commonly affected organ. The aim of this prospective therapy study was to evaluate the clinical effect of autologous, monocyte-derived dendritic cell (DC) therapy in canine hemangiosarcoma stage II after splenectomy. Dogs (n=452) diagnosed with splenic hemangiosarcoma that underwent splenectomy were enrolled. Of these, 42 dogs with stage II entered the DC therapy study. The median survival time for the total group of 42 dogs was 203 days. The median survival for the group (n=34) that received the full DC therapy (≥3 vaccines) was 256 days, with a 29 % one-year survival rate and a hazard ratio of 0.30, adjusted to age and bodyweight (P=0.010). We further observed a significant increase in DC yield after each application and demonstrated that DC yield at the beginning of treatment is significantly related to patient survival. While further evidence is needed, we conclude that autologous, monocyte-derived DC therapy is a viable alternative to standard treatment methods of canine splenic stage II hemangiosarcoma.
Find similar cases for your pet
PetCaseFinder finds other peer-reviewed reports of pets with the same symptoms, plus a plain-English summary of what was tried across them.
Search related cases →Original publication on PubMed: https://pubmed.ncbi.nlm.nih.gov/39004264/